Late Focal Pancreatic Metastasis of Renal Cell Carcinoma

Sahin, Mustafa; Foulis, Alan A.K.; Poon, F. W.; Imrie, C. W.

doi:10.1159/000018591

Cited by 33 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Renal Cell Carcinoma (RCC), melanoma, lung cancer, colorectal cancer, gynaecological and breast cancer are known to metastasize to the pancreas [11–15]. Solitary metastasis to the pancreas account from 2 to 5 % in clinical studies [15, 16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?

et al. 2016

View full text Add to dashboard Cite

BackgroundMetastatic renal cell cancer is a heterogeneous disease due to its diverse morphological features, the prognostic categories based on clinical criteria. Sometimes indolent course without any significant symptoms can be differentiated before the introduction of novel targeted agents. This observation led to interest in a strategy of deferring systemic therapy in the era of effective systemic therapies.Case presentationWe report of a 78-year-old Moroccan man with pancreatic metastasis from renal cell carcinoma which occurred 14 years from right nephrectomy. Indolent disease based on body computed tomography imaging with 4 years follow-up was recognized. Active surveillance with deferred antiangiogenic multikinase inhibitor at disease progression was proposed. Nowadays, the patient is under oncological follow-up, he is in a good state of health, and he is disease-free for 48 months from the diagnosis of the tumor and for 20 months from the start of the treatment with SunitinibConclusionsActive surveillance before target therapy may be a suitable approach to ensure long progression-free survival with minimal side-effects and better quality of life in asymptomatic, low-volume, metastatic disease. Further prospective studies with biomarker validation are required to define the patients most likely to benefit from this approach.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Solitary metastasis to the pancreas account from 2 to 5 % in clinical studies [15, 16]. They can occur many years after its removal especially if the tumor is well- differentiated.…”

Section: Discussionmentioning

confidence: 99%

Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Latent distant metastasis is characteristic of RCC and manifests more than 10 years after nephrectomy in about 10% of patients. 3,11 Thus, patients must be monitored for more than 10 years after radical surgery for RCC to detect recurrence early.…”

Section: Discussionmentioning

confidence: 99%

Resection of a Solitary Pancreatic Metastasis from Renal Cell Carcinoma with a Gallbladder Carcinoma: Report of a Case

et al. 2004

View full text Add to dashboard Cite

Most metastatic pancreatic tumors are detected at an advanced stage and are not considered suitable for surgery; however, resection is sometimes indicated for a solitary pancreatic metastasis from renal cell carcinoma (RCC) and improves the prognosis. We report such a case, in which the hilar liver was resected with lymph node dissection and distal pancreatectomy. Histological examination revealed regional lymph node metastasis of gallbladder carcinoma (GBC), but all the surgical margins were free of cancer. Postoperative extra-beam radiation therapy was delivered to the hepatic portal lesion to prevent GBC recurrence. The patient remains disease-free 14 months after the completion of radiation therapy. Thus, if all affected areas can be resected, the prognosis associated with pancreatic metastasis from RCC may be favorable.

show abstract

“…The records of these five patients were reviewed. Survival rates were determined in our patients and from a review of the relevant literature, including 22 patients with well documented surgically treated pancreatic metastases from RCC . The Kaplan‐Meier method was used to estimate 3‐ and 5‐year survival rates.…”

Section: Methodsmentioning

confidence: 99%

Results of duodenopancreatectomy for solitary pancreatic metastasis from renal cell carcinoma

Tuech

Pessaux

Chautard

et al. 1999

Journal of Hepato-Biliary-Pancreatic Surgery

View full text Add to dashboard Cite

The pancreas is an uncommon site of metastasis from renal cell carcinoma. We present five patients with solitary pancreatic metastasis from renal cell carcinoma located in the head of the pancreas, treated by duodenopancreatectomy. There were no perioperative deaths. Mean survival was 48 months; three patients were alive at the end of the study (at 27, 46, and 88 months, respectively) and two patients died, at 13 and 70 months. The 3- and 5-year survival rates of our patients together with 22 previously reported patients were 86% and 68%, respectively. We advocate aggressive surgical treatment when the metastatic disease is limited to the pancreas.

show abstract

Late Focal Pancreatic Metastasis of Renal Cell Carcinoma

Cited by 33 publications

References 3 publications

Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?

Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?

Resection of a Solitary Pancreatic Metastasis from Renal Cell Carcinoma with a Gallbladder Carcinoma: Report of a Case

Results of duodenopancreatectomy for solitary pancreatic metastasis from renal cell carcinoma

Contact Info

Product

Resources

About